Research
Hormonal
GLP-1 receptor agonists have shown remarkable weight loss potential comparable to bariatric interventions.
GLP-1 receptor agonists may be a viable non-invasive alternative for weight loss in some patients.
StrongSupportsmedium confidence
Recently, glucagon-like insulinotropic peptide-1 receptor agonists (GLP) and the GLP-1/gastric inhibitory polypeptide co-agonist–Tirzepatide have shown remarkable weight loss potential, which is at par with bariatric interventions in some patients.
Why this rating
The claim is based on recent findings regarding GLP-1 receptor agonists.
Source
Bariatric and endo-bariatric interventions for diabetes: What is the current evidence?
Sunetra Mondal et al. · World Journal of Diabetes · 2024
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →